{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:44:47Z","timestamp":1789587887058,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG3H1552"],"award-info":[{"award-number":["CMRPG3H1552"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"crossref","award":["107 2320 B 006 070 MY3"],"award-info":[{"award-number":["107 2320 B 006 070 MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better pleiotropic effects of SGLT2 inhibitors. However, no published data are currently available to directly compare glycemic and pleiotropic effects in real-world type 2 diabetes patients initiating SGLT2 inhibitors or DPP4 inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We conducted a retrospective cohort study by analyzing the Chang Gung Research Database, the largest multi-institutional electronic medical records database in Taiwan. We included patients newly receiving SGLT2 inhibitor or DPP4 inhibitor intensification therapy for type 2 diabetes from 2016 to 2017. We matched SGLT2 inhibitor users to DPP4 inhibitor users (1:4) by propensity scores to ensure comparable characteristics between the groups. We primarily evaluated 1-year post-treatment changes of hemoglobin A1c (HbA1c) after SGLT2 inhibitor or DPP4 inhibitor initiation, using two-tailed independent t-test. We also evaluated post-treatment changes in body weight, systolic blood pressure (SBP), alanine aminotransferase (ALT) and estimated glomerular filtration rate (eGFR) values, associated with SGLT2 inhibitors and DPP4 inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified a cohort of 2028 SGLT2 inhibitors and 8112 matched DPP4 inhibitors new users. SGLT2 inhibitors and DPP4 inhibitors showed similar HbA1c reductions (\u2212\u20091.0 vs. \u2212\u20091.1%; P\u2009=\u20090.076), but patients receiving SGLT2 inhibitors had greater improvements in body weight (\u2212\u20091.5 vs. \u2212\u20091.0\u00a0kg; P\u2009=\u20090.008), SBP (\u2212\u20092.5 vs. \u2212\u20090.7\u00a0mmHg; P\u2009&lt;\u20090.001) and ALT values (\u2212\u20094.1 vs. \u2212\u20090.0\u00a0U\/l; P\u2009&lt;\u20090.001) and smaller declines in eGFR values (\u2212\u20092.0 vs. \u2212\u20093.5\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>; P\u2009&lt;\u20090.001) when compared to DPP4 inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SGLT2 inhibitors had glucose-lowering effects comparable to those of DPP4 inhibitors but more favorable pleiotropic effects on body weight, ALT and eGFR changes, potentially improving type 2 diabetes patients\u2019 cardio-metabolic disease risks.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-0990-2","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T11:03:27Z","timestamp":1581505407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Shih-Chieh","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swu-Jane","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jui","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuk-Ying","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yea-Huei","family":"Kao Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-7652","authenticated-orcid":false,"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"990_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83.","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"990_CR2","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103\u201323.","journal-title":"Diabetes Care"},{"key":"990_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2337\/dc06-1539","volume":"30","author":"KG Tolman","year":"2007","unstructured":"Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734\u201343.","journal-title":"Diabetes Care"},{"key":"990_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2337\/dc17-1590","volume":"41","author":"SH Wild","year":"2018","unstructured":"Wild SH, Walker JJ, Morling JR, et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41:341\u20137.","journal-title":"Diabetes Care"},{"key":"990_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","volume":"65","author":"SM Francque","year":"2016","unstructured":"Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65:425\u201343.","journal-title":"J Hepatol"},{"key":"990_CR6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/dom.13346","volume":"20","author":"HJ Curtis","year":"2018","unstructured":"Curtis HJ, Dennis JM, Shields BM, et al. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. 2018;20:2159\u201368.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.13477","volume":"21","author":"GK Dawwas","year":"2019","unstructured":"Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21:28\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-018-0737-5","volume":"17","author":"YG Kim","year":"2018","unstructured":"Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Cardiovasc Diabetol. 2018;17:91.","journal-title":"Cardiovasc Diabetol"},{"key":"990_CR9","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319:1580\u201391.","journal-title":"JAMA"},{"key":"990_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-017-0575-x","volume":"16","author":"S Gautam","year":"2017","unstructured":"Gautam S, Agiro A, Barron J, Power T, Weisman H, White J. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol. 2017;16:93.","journal-title":"Cardiovasc Diabetol"},{"key":"990_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/dom.13047","volume":"20","author":"Z Wang","year":"2018","unstructured":"Wang Z, Sun J, Han R, et al. Efficacy and safety of sodium\u2013glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:113\u201320.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR12","doi-asserted-by":"publisher","first-page":"e0125879","DOI":"10.1371\/journal.pone.0125879","volume":"10","author":"ES Mearns","year":"2015","unstructured":"Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS ONE. 2015;10:e0125879.","journal-title":"PLoS ONE"},{"key":"990_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","volume":"42","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42:25\u201332.","journal-title":"Diabetes Metab"},{"key":"990_CR14","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015\u201321.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"990_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/dom.13178","volume":"20","author":"S Chatterjee","year":"2018","unstructured":"Chatterjee S, Davies MJ, Khunti K. What have we learnt from \u201creal world\u201d data, observational studies and meta-analyses. Diabetes Obes Metab. 2018;20(Suppl 1):47\u201358.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","volume":"28","author":"SC Shao","year":"2019","unstructured":"Shao SC, Chan YY, Kao Yang YH, et al. The Chang Gung Research Database\u2014a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019;28:593\u2013600.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"990_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-019-0919-9","volume":"18","author":"SC Shao","year":"2019","unstructured":"Shao SC, Chang KC, Hung MJ, et al. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. Cardiovasc Diabetol. 2019;18:120.","journal-title":"Cardiovasc Diabetol"},{"key":"990_CR18","doi-asserted-by":"publisher","first-page":"e000742","DOI":"10.1136\/bmjdrc-2019-000742","volume":"7","author":"SC Shao","year":"2019","unstructured":"Shao SC, Lin YH, Chang KC, et al. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care. 2019;7:e000742.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"990_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/dom.13875","volume":"22","author":"SC Shao","year":"2020","unstructured":"Shao SC, Chang KC, Chien RN, et al. Effects of sodium\u2013glucose co-transporter-2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes: a multi-institutional cohort study. Diabetes Obes Metab. 2020;22:128\u201334.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"990_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/pds.3263","volume":"21","author":"JA Rassen","year":"2012","unstructured":"Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 2):69\u201380.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"990_CR21","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.2787","volume":"26","author":"O Harel","year":"2007","unstructured":"Harel O, Zhou XH. Multiple imputation: review of theory, implementation and software. Stat Med. 2007;26:3057\u201377.","journal-title":"Stat Med"},{"key":"990_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1463-1326.2010.01248.x","volume":"12","author":"RA Cantrell","year":"2010","unstructured":"Cantrell RA, Alatorre CI, Davis EJ, et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab. 2010;12:845\u201357.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/1753-0407.12257","volume":"8","author":"R Aronson","year":"2016","unstructured":"Aronson R, Orzech N, Ye C, Goldenberg R, Brown V. Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: insights into the functionally refractory patient from the LMC Diabetes Registry database. J Diabetes. 2016;8:76\u201385.","journal-title":"J Diabetes"},{"key":"990_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, K\u00e4r\u00e4j\u00e4m\u00e4ki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"990_CR25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7:684\u201394.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"990_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1467-789X.2005.00175.x","volume":"6","author":"NF Chu","year":"2005","unstructured":"Chu NF. Prevalence of obesity in Taiwan. Obes Rev. 2005;6:271\u20134.","journal-title":"Obes Rev"},{"key":"990_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","volume":"56","author":"YG Kim","year":"2013","unstructured":"Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696\u2013708.","journal-title":"Diabetologia"},{"key":"990_CR28","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2337\/dc14-1630","volume":"38","author":"L Van Gaal","year":"2015","unstructured":"Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161\u201372.","journal-title":"Diabetes Care"},{"key":"990_CR29","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481\u20136.","journal-title":"Diabetes Care"},{"key":"990_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.diabet.2018.01.017","volume":"44","author":"BM Mishriky","year":"2018","unstructured":"Mishriky BM, Tanenberg RJ, Sewell KA, Cummings DM. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2018;44:112\u201320.","journal-title":"Diabetes Metab"},{"key":"990_CR31","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/obr.12755","volume":"19","author":"PC Lee","year":"2018","unstructured":"Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium\u2013glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19:1630\u201341.","journal-title":"Obes Rev"},{"key":"990_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13098-017-0297-y","volume":"9","author":"Y Thewjitcharoen","year":"2017","unstructured":"Thewjitcharoen Y, Yenseung N, Malidaeng A, et al. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. Diabetol Metab Syndr. 2017;9:96.","journal-title":"Diabetol Metab Syndr"},{"key":"990_CR33","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","volume":"37","author":"JR Sowers","year":"2001","unstructured":"Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053\u20139.","journal-title":"Hypertension"},{"key":"990_CR34","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1111\/dom.13819","volume":"21","author":"C Deerochanawong","year":"2019","unstructured":"Deerochanawong C, Chan SP, Matawaran BJ, et al. Use of sodium\u2013glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: an Asian perspective and expert recommendations. Diabetes Obes Metab. 2019;21:2354\u201367.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2337\/dc16-1787","volume":"40","author":"F Bril","year":"2017","unstructured":"Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017;40:419\u201330.","journal-title":"Diabetes Care"},{"key":"990_CR36","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/00325481.2016.1242366","volume":"128","author":"S Chen","year":"2016","unstructured":"Chen S, Guo X, Chen Y, Dong S, Sun Y. Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: a cross-sectional study from China. Postgrad Med. 2016;128:770\u20136.","journal-title":"Postgrad Med"},{"key":"990_CR37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.atherosclerosis.2008.12.012","volume":"205","author":"KE Yun","year":"2009","unstructured":"Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis. 2009;205:533\u20137.","journal-title":"Atherosclerosis"},{"key":"990_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.diabet.2018.08.001","volume":"44","author":"HS Bajaj","year":"2018","unstructured":"Bajaj HS, Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R. SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes. Diabetes Metab. 2018;44:493\u20139.","journal-title":"Diabetes Metab"},{"key":"990_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","volume":"45","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213\u201323.","journal-title":"Diabetes Metab"},{"key":"990_CR40","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/sj.ki.5000270","volume":"69","author":"BR Hemmelgarn","year":"2006","unstructured":"Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006;69:2155\u201361.","journal-title":"Kidney Int"},{"key":"990_CR41","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21:1237\u201350.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3803\/EnM.2019.34.1.80","volume":"34","author":"JH Bae","year":"2019","unstructured":"Bae JH, Kim S, Park EG, Kim SG, Hahn S, Kim NH. Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Endocrinol Metab. 2019;34:80\u201392.","journal-title":"Endocrinol Metab"},{"key":"990_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.diabet.2017.07.011","volume":"44","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ, Delanaye P. Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes Metab. 2018;44:101\u201311.","journal-title":"Diabetes Metab"},{"key":"990_CR44","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","volume":"32","author":"A Mima","year":"2018","unstructured":"Mima A. Renal protection by sodium\u2013glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complicat. 2018;32:720\u20135.","journal-title":"J Diabetes Complicat"},{"key":"990_CR45","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/jdi.12971","volume":"10","author":"T Kadowaki","year":"2019","unstructured":"Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME\u00ae trial. J Diabetes Investig. 2019;10:760\u201370.","journal-title":"J Diabetes Investig"},{"issue":"Suppl 2","key":"990_CR46","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15-3006","volume":"39","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165\u201371.","journal-title":"Diabetes Care"},{"key":"990_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93:231\u201344.","journal-title":"Kidney Int"},{"key":"990_CR48","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"P Fioretto","year":"2018","unstructured":"Fioretto P, Del Prato S, Buse JB. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab. 2018;20:2532\u201340.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR49","doi-asserted-by":"publisher","first-page":"1423191","DOI":"10.1155\/2016\/1423191","volume":"2016","author":"YG Kim","year":"2016","unstructured":"Kim YG, Byun J, Yoon D, et al. Renal protective effect of DPP-4 inhibitors in type 2 diabetes mellitus patients: a cohort study. J Diabetes Res. 2016;2016:1423191.","journal-title":"J Diabetes Res"},{"issue":"4 Suppl 2","key":"990_CR50","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1681\/ASN.2005121343","volume":"17","author":"P Fioretto","year":"2006","unstructured":"Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17(4 Suppl 2):S86\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"990_CR51","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.ajkd.2008.04.011","volume":"52","author":"CP Kovesdy","year":"2008","unstructured":"Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis. 2008;52:766\u201377.","journal-title":"Am J Kidney Dis"},{"key":"990_CR52","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1111\/dom.13488","volume":"20","author":"F Prattichizzo","year":"2018","unstructured":"Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A, et al. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20:2515\u201322.","journal-title":"Diabetes Obes Metab"},{"key":"990_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"DD Adingupu","year":"2019","unstructured":"Adingupu DD, G\u00f6pel SO, Gr\u00f6nros J, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(\u2212\/\u2212) mice. Cardiovasc Diabetol. 2019;18:16.","journal-title":"Cardiovasc Diabetol"},{"key":"990_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17:73.","journal-title":"Cardiovasc Diabetol"},{"key":"990_CR55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:132.","journal-title":"Cardiovasc Diabetol"},{"key":"990_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"990_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","volume":"18","author":"AY Kluger","year":"2019","unstructured":"Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18:99.","journal-title":"Cardiovasc Diabetol"},{"key":"990_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","volume":"25","author":"MS Usman","year":"2018","unstructured":"Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:495\u2013502.","journal-title":"Eur J Prev Cardiol"},{"key":"990_CR59","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ihj.2018.08.022","volume":"70","author":"AK Pancholia","year":"2018","unstructured":"Pancholia AK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart J. 2018;70:915\u201321.","journal-title":"Indian Heart J"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-0990-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-0990-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-0990-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T09:33:04Z","timestamp":1613035984000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-0990-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-0990-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Chang Gung Medical Foundation (ID: 201801493B0). The IRB waived the consent requirement because all patients\u2019 personal identities are encrypted by anonymous identification numbers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}